Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Human Metabolome TechnologiesTSE:6090 +3.37%62 Debt-to-EBITDA is 0.16 as of Mar. 2026, which is 66% below its 10-year median of 0.47. GuruFocus rates TSE:6090 with a GF Score™ of 62/100 and a GF Value™ of 円693.69 (Fairly Valued). The stock has 3 warning signs investors should review. Among 112 Medical Diagnostics & Research companies, Human Metabolome Technologies ranks better than 83.93% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Human Metabolome Technologies's Debt-to-EBITDA or its related term are showing as below:
TSE:6090'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.83 Med: 0.47 Max: 1.41
Current: 0.26
During the past 13 years, the highest Debt-to-EBITDA Ratio of Human Metabolome Technologies was 1.41. The lowest was -2.83. And the median was 0.47.
TSE:6090's Debt-to-EBITDA is ranked better than 83.93% of 112
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.195
vs TSE:6090: 0.26
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Human Metabolome Technologies Debt-to-EBITDA Related Terms
Human Metabolome Technologies Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies Debt-to-EBITDA Chart
TSE:6090 vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Human Metabolome Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Human Metabolome Technologies Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Human Metabolome Technologies's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Human Metabolome Technologies (TSE:6090) has a Debt-to-EBITDA of 0.16 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Human Metabolome Technologies. This is 66% below median its historical median of 0.47. According to the industry distribution chart, Human Metabolome Technologies ranks #18 out of 112 companies in the Medical Diagnostics & Research industry, placing it in the top 16.1%.
Is Human Metabolome Technologies' Debt-to-EBITDA too high?
Human Metabolome Technologies' current Debt-to-EBITDA of 0.16 is 66% below median its 10-year median of 0.47. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.20. Human Metabolome Technologies' value of 0.16 is 92.7% below this industry median. Based on the distribution chart, Human Metabolome Technologies ranks #18 out of 112 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Human Metabolome Technologies has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Human Metabolome Technologies ranks #18 out of 112 companies for Debt-to-EBITDA. This places Human Metabolome Technologies in the top 16% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.20. Human Metabolome Technologies' value of 0.16 is 92.7% below this benchmark. While the company's 10-year median is 0.47 vs. the industry median of 2.20, Human Metabolome Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.20, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Human Metabolome Technologies's current Debt-to-EBITDA of 0.16 is 92.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Human Metabolome Technologies. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Human Metabolome Technologies's current Debt-to-EBITDA is 0.16, which is 66% below median its own 10-year median of 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Fairly Valued. The stock's GF Value™ is 円693.69, compared to a current price of 円645.00 — trading 7% below its estimated fair value. The current Debt-to-EBITDA is 0.16, which is 66% below median its 10-year median of 0.47 and 92.7% below the Medical Diagnostics & Research industry median of 2.20. Human Metabolome Technologies' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current Debt-to-EBITDA is 0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?
Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be undervalued.
The current stock price of 円645.00 is trading 7% below its estimated GF Value™ of 円693.69.
GuruFocus considers Human Metabolome Technologies to be Fairly Valued.
Key valuation signals for TSE:6090:
Debt-to-EBITDA: 0.16 (66% below median its 10-year median of 0.47)
GF Value™: 円693.69 vs. price of 円645.00 (7% below fair value)
Industry Position: 92.7% below the Medical Diagnostics & Research median (#18 of 112)
No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6090 has been successfully added to your 
